profiles of older patients. [10] Frailty and comprehensive geriatric assessment (CGA) are being incorporated to guide treatment decisions for cancer patients. [11, 12] However, the value of a geriatric assessment (GA) for MM patients in China has not yet been prospectively evaluated. We assessed the predictive role of a baseline GA in 628 newly diagnosed MM patients to define a frailty score and assess the influence of this score on clinical outcomes and toxicity.
meThods
The study was a multicenter retrospective study that enrolled newly diagnosed inpatients from six hospitals from June 2011 to June 2013. Six hundred and twenty-eight patients were enrolled. The patients' demographic features, clinical features, treatments, and outcome data were collected and analyzed [ Table 1 ]. MM was defined according to the criteria of the International Myeloma Working Group (IMWG). [1] This study was retrospective, and all patients' data remained anonymous. Therefore, the requirement to obtain informed consent was waived. This study was complied with the Declaration of Helsinki and was approved by Beijing Peoples' Hospital Ethics Committees.
The primary objective of this analysis was to identify a simple scoring system based on geriatric parameters to predict overall survival (OS). The secondary objectives included an evaluation of the impact of the frailty scoring system on treatment-related toxicity and progression-free survival (PFS).
The GA consisted of the following three tools: Katz's Activities of Daily Living (ADL) index, Lawton's Instrumental Activities of Daily Living (IADL) index, and the Charlson Comorbidity Index (CCI). The ADL and the IADL scales were adopted to assess the self-care activities, tasks of household management and independence status. The patients' general conditions, ISS scores, beta-2-microglobulin and albumin levels, and some chromosomal abnormalities were assessed and collected. We also assessed adverse events (AEs) in these patients, and we graded these events according to the National Cancer Institute Common Terminology Criteria (NCI-CTC) for Adverse Events version 3.0.
Statistical analysis
We used the Kaplan-Meier method to estimate survival and compared between risk groups using log-rank testing. Estimates of the predictive effect of GA for OS were expressed as hazard ratios (HRs). A value of P ≤ 0.05 was considered to be significant differences. The statistical analysis was performed using Statistical Product and Service Solutions (SPSS) version 22.0 statistical software (SPSS Inc., Chicago, IL, USA).
resUlTs
This retrospective study included 628 newly diagnosed MM patients. The median age was 58 years, and the majority of patients (68.79%) were <65 years [ In this real practice study of MM, a multivariate Cox regression model showed that geriatric components influenced OS. In the frail patients, including those >75 years old, functional declines indicated by the ADL and IADL scores and the presence of comorbidities were associated with worse OS. Reduced OS was observed for patients aged >75 years (HR: 1.25), for patients with ADL scores ≤4 (HR: 1.36) and IADL scores ≤5 (HR: 1.31), and for patients with CCI scores ≥2 (HR: 1.11) [ Table 2 ]. The OS did not differ between the fit and the intermediately fit patients. An ISS-adjusted multivariate analysis revealed that the risk of death was higher for patients older than 75 years. The proportions of the frail patients in the ISS I, II, and III risk groups and the OSs of these groups are illustrated [ Table 3 ]. Grade 3 or higher hematologic AEs were documented in 45 (35.4%) fit, 34 (34%) intermediately fit, and 121 (30.2%) frail patients. The risks of developing a grade ≥3 hematologic AEs were not significantly higher in the intermediately fit (HR: 0.99, 95% confidence score identified six groups. The median follow-up time was 13.4 months (8-33 months). The survival curves for these six groups are shown in Figure 1 . The frail, ISS II/ III patients were considered to be very high-risk patients and exhibited a 3-year OS of 49%. The fit, ISS I patients were deemed to be low-risk patients and exhibited the best prognoses and a 3-year OS of 90%.
discUssion
The median age observed in the study was similar to the age reported by Dr. Lu et al. [13] This retrospective analysis revealed that the frailty score, which combined age, functional status and comorbidities, was associated with survival and toxicity and could be useful to guide dosage adjustments for the treatment of Chinese MM patients. The frailty profile was relevant to progression, nonhematologic AEs and treatment discontinuation irrespective of the ISS stage and type. The study validated the recent IMWG publication of Dr. Palumbo et al. [14] In our analysis, the 3-year OS rates were 63% in the fit, 63% in the intermediately fit and 50% in the frail patients. In our results, OS did not significantly differ between groups, primarily because the doses were reduced during the treatment of the fit patients at some centers. The reduced survival of the frail patients was due to reductions in doses and age. A significantly higher cumulative incidence of nonhematologic toxicities and a significantly increased rate of drug discontinuation were observed in the frail patients compared with the fit patients, and the nonhematologic AEs and drug discontinuations might have reduced survival. The findings suggest that dose reductions reduced the occurrence of hematological toxicity but did not affect the toxicity of hematology.
Following the combination of the frailty score with the established ISS, the 3-year OS rates were found to be 49% in the frail, ISS II/III group and 90% in the fit, ISS I group. Maybe people with more advanced stage might have worse physical activity and tolerance with regimen. We hope the combination of the two independent parameters will produce a single index that significantly improved the prognostic Figure 1 : OSs of the patients classified into six categories according to recursive partitioning analysis following the combination of two independent prognostic scores, i.e., the frailty score and the ISS score. OSs: Overall survivals; ISS: International Staging System. value and will consequently serve as an important prediction strategy in the future.
The chronological order of the patient's age, the patient's performance status, and the doctor's clinical judgment are insufficient characteristics to define vulnerable populations. The GA could be used in routine clinical practice and in research to ensure that appropriate elderly patients were selected to facilitate more accurate cross-trial comparisons. Frail patients might benefit from mild methods or even palliative/less supportive treatment. [15] [16] [17] The power of this analysis was great due to the widely representative and fairly homogeneous group of real-world data provided by the six Chinese centers. The GAs were prospectively obtained prior to the initiation of chemotherapy and reflected the patients' baseline health statuses rather than the toxicities induced by the therapies. Older people required special care in terms of treatment decisions, and efficacy and side effects must be carefully balanced.
The study is subject to some limitations. This study was retrospective, the value of the information was not very high, and the ADL and IADL scores from the different centers were not uniform. The treatments differed, and these differences biased the survival time data. Dose adjustments for the frail patients resulted in weak doses, and significant differences were consequently not observed between the fit and frail patients.
In conclusion, this study of real-world MM treatment in China revealed that in the mainland of China, the majority of patients were young, in the later ISS stages, and in poor physical condition. The fit, ISS I patients survived the longest. The specific disease risk factors of a patient need to be established prior to selecting a treatment. 
